No Data
No Data
Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible Disclosure Delay About June 2024 FDA Inspection of Manufacturing Facility Hagens Berman
Express News | FDA: Mylan Institutional's Rifampin, Injection, 600 Mg/10 Ml Available; Inventory Expires 10/31/2025 - Website
Jefferies Maintains Viatris(VTRS.US) With Buy Rating, Cuts Target Price to $13
Jefferies Adjusts Viatris Price Target to $13 From $15, Maintains Buy Rating
Biocon Biologics Announces Positive Results From Phase 3 Study of Yesintek Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
Viatris to Present at the Barclays 27th Annual Global Healthcare Conference